Estimating the direct costs of bowel cancer services provided by the National Health Service in England

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 4, 2010, Pages 362-369

  Bending, Matthew W ^a   Trueman, Paul ^b,c   Lowson, Karin V ^a   Pilgrim, Hazel ^d   Tappenden, Paul ^d   Chilcott, Jim ^d   Tappenden, Janine ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Department of Health Economics ^*  (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Colorectal neoplasms; Cost of illness; Economic; Models

Indexed keywords

COLORECTAL NEOPLASMS; COST OF ILLNESS; DIRECT COSTS; ECONOMIC EVALUATIONS; ENGLAND; HIGH-RISK PATIENTS; LOCAL DECISIONS; NATIONAL HEALTH SERVICES; PRIMARY CARE; SURGICAL PROCEDURES; WHOLE SYSTEMS;

BUDGET CONTROL; COST ACCOUNTING; COSTS; ECONOMICS; ESTIMATION; HEALTH RISKS; INVESTMENTS; TUMORS;

COST BENEFIT ANALYSIS;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; HEALTH CARE COST; HUMAN; INTESTINE CANCER; NATIONAL HEALTH SERVICE; RESOURCE ALLOCATION; UNITED KINGDOM;

COLORECTAL NEOPLASMS; COST OF ILLNESS; COSTS AND COST ANALYSIS; CRITICAL PATHWAYS; ENGLAND; HEALTH CARE COSTS; HUMANS; STATE MEDICINE;

EID: 78649989126     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310001078     Document Type: Article

References (31)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer: MOSAIC trial. N Engl J Med. 2004;350:2343-2351.
2. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
3. Ciccolallo L, Capocaccia R, Coleman M, et al. Survival differences between European and US patients with colorectal cancer: Role of stage at diagnosis and surgery. Gut. 2005;54:268-273.
4. ColemanM, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14(Suppl 5):128-149.
5. Decisioneering. Crystall ball. Denver, CO: Decisioneering; 2000.
6. Department of Health. World class commissioning. Commissioning assurance handbook. London: Department of Health; 2008.
7. Department of Health. Hospital episode statistics (2003/2004). 2005. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID= 1937&categoryID=245 (accessed January 18, 2010).
8. Department of Health. NHS reference costs 2005. London: Department of Health; 2006. Report No: 4664.
9. Department of Health. Cancer Reform Strategy. London: Department of Health; 2007. Report No: 9092.
10. Forman D, Stockton D, Moller H, et al. Cancer prevalence in the UK: Results from the EUROPREVAL study. Ann Oncol. 2003;14:648-654.
11. Garthwaite P, Chilcott J, Jenkinson D, Tappenden P. Use of expert knowledge in evaluating costs and benefits of alternative service provisions: A case study. Int J Technol Assess Health Care. 2008;24:350-357.
12. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: Systematic review and economic evaluation. Health Technol Assess. 2008;12:iii-ix, xi-162.
13. Mawdsley S, Glynne-Jones R, Grainger J, et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Bio Phys. 2005;63:745-752.
14. Microsoft. Excel 2003. Redmond,WA:Microsoft Corporation; 2003.
15. Netten A, Curtis L. Unit costs of health and social care 2005. Canterbury, Kent: Personal Social Services Research Unit, University of Kent at Canterbury; 2005.
16. O'Hagan A, Buck C, Daneshkhah A, et al. Uncertain judgements: Eliciting experts' probabilities. Chichester: John Wiley & Sons; 2006.
17. Office for National Statistics. Cancer statistics registrations: Registrations of cancer diagnosed in 2003, England. London: Office for National Statistics; 2003. http://www. statistics.gov.uk/downloads/theme-health/MB1-34/ MB1-34. pdf.
18. Office for National Statistics. Cancer statistics registrations. London: Office for National Statistics; 2006 http://www. statistics.gov.uk/downloads/ theme-health/MB1-37/MB1-37-2006.pdf (accessed January 18, 2010).
19. Office for National Statistics. Mortality statistics: Review of the Registrar General on deaths by cause, sex, and age, in England and Wales, 2007. London: Office for National Statistics; 2007. http://www.statistics.gov.uk/ downloads/theme-health/DR2007 /DR-07-2007.pdf (accessed January 18, 2010).
20. Pandor A, Eggington S, Paisley S, et al. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: Systematic review and economic evaluation. Health Technol Assess. 2006;10:iii-iv, xi-xiv, 1-185.
21. Pilgrim H, Tappenden P, Chilcott J, et al. The costs and benefits of bowel cancer service developments using discrete event simulation. J Oper Res Soc. 2009;60:1305-1314.
22. Ruta D, Mitton C, Bate A, Donaldson C. Programme budgeting andmarginal analysis: Bridging the divide between doctors and managers. Br Med J. 2005;330:1501-1503.
23. Sebag-Montefiore D, Steele R, Quirke P, et al. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. ASCO Annual Meeting 2006.
24. Seymour MT. Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) Trial. European Society of Medical Oncology Conference 2004.
25. Tappenden P, Chilcott J, Eggington S, et al. Option appraisal of population-based colorectal cancer screening in England. Gut. 2007;56:677-684.
26. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11:1-128, iii-iv.
27. The Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer: COST trial. N Engl J Med. 2004;350:2050-2059.
28. Trueman P, Lowson K, Bending M, et al. Bowel cancer services: Costs and benefits literature review. Report to the Department of Health. London: Department of Health; 2007.
29. TwelvesC,Wong A, NowackiM, et al. Capecitabine as adjuvant treatment for stage III colon cancer: X-ACT trial. N Engl JMed. 2005;352:2696-2704.
30. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation. Health Technol Assess. 2003;7: 1-93.
31. Yabroff K, Mariotto A, Feuer E, Brown M. Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ. 2008;17:947-959.